Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.
Philippe L BedardShuli LiKari B WisinskiEddy Shih-Hsin YangSewanti A LimayeEdith P MitchellJames A ZwiebelJeffrey A MoscowRobert C GrayVictoria WangLisa Meier McShaneLawrence V RubinsteinDavid R PattonP Mickey WilliamsStanley R HamiltonBarbara A ConleyCarlos L ArteagaLyndsay N HarrisPeter J O'DwyerAlice P ChenKeith T FlahertyPublished in: JCO precision oncology (2022)
Although afatinib did not meet the prespecified threshold for antitumor activity in this heavily pretreated cohort, the response in a rare tumor type is notable. The safety profile of afatinib was consistent with prior studies.
Keyphrases
- epidermal growth factor receptor
- phase ii study
- advanced non small cell lung cancer
- tyrosine kinase
- open label
- endothelial cells
- locally advanced
- phase ii
- study protocol
- signaling pathway
- clinical trial
- squamous cell carcinoma
- pluripotent stem cells
- randomized controlled trial
- placebo controlled
- radiation therapy
- bone marrow
- cell therapy
- case control
- mesenchymal stem cells